LLMs in SLE: From Patient Education to Clinical Decision Support The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical https://t.co/0rhada36Ji

NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route. https://t.co/8eZyDxL7wu https://t.co/Nvbj1NQb5A

NEW FROM ACR: Clinical responses with an IL-23i in patients with active PsA See the efficacy and safety data through ~5 years in the RheumNow poster hall. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/mT6WkG6Q6D https://t.co/nXZSaHj16m

When Patients with RA Choose Their Treatment, Outcomes Are Better — Here's the Data Dr. Aurelie Najm discusses abstract OP0204 presented in London at the EULAR 2026 Congress. https://t.co/7mjclBgobB https://t.co/o9fuV5FRMv

Obinutuzumab drives histologic remission in lupus nephritis At #EULAR2026, new data from the phase III REGENCY trial add to the case for obinutuzumab in lupus nephritis. Investigators report deep intrarenal B-cell depletion and significantly higher rates of histological https://t.co/13HY1qIDcj

RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest RA inflammation may be under control, but RA-associated ILD remains a major challenge. At #EULAR2026, experts highlighted that ILD is one of the few RA outcomes not improving in the biologic era. Three new https://t.co/Qujhl3ktRp

What’s New in Psoriatic Arthritis: A Whirlwind Tour At #EULAR2026, Prof. Dennis McGonagle highlighted three key PsA trends: the rise of single-cell and spatial transcriptomics, progress toward personalized care (though not yet fully realized), and the next frontier of defining https://t.co/zN4K92UnW9

RA-ILD: Screening risk and genetic susceptibility Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development. https://t.co/IABp8NhUtS https://t.co/j8UHK2GRd7

Vasculitis Updates: Glucocorticoid use in AAV and GCA Vasculitis Updates: Glucocorticoids are the cornerstone of initial therapy for AAV and GCA—quickly reducing inflammation and preserving organs. EULAR has issued recommendations on glucocorticoid use in ANCA‑associated and https://t.co/hIOKyXDxyb

Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London. https://t.co/ir9pdwBnH4 https://t.co/yjjgcA2TRv

Renal Biopsies in SLE Dr. Andrea Fava reporting from EULAR 2026 in London. https://t.co/naCyEAutbb https://t.co/XgdiXY3hiO